Vasoactive intestinal peptide inhibits IL-8 production in human monocytes

被引：32

作者：

Delgado, M ^{[1
]}

Ganea, D

机构：

[1] Rutgers State Univ, Dept Biol Sci, Newark, NJ 07102 USA

[2] Univ Complutense Madrid, Fac Biol, Dept Biol Celular, E-28040 Madrid, Spain

来源：

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS | 2003年 / 301卷 / 04期

关键词：

neuroimmunology; neuropeptides; monocytes; chemokines; inflammation; chemotaxis;

D O I：

10.1016/S0006-291X(03)00059-7

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Vasoactive intestinal peptide (VIP), a neuropeptide present in the lymphoid microenvironment, acts as a potent anti-inflammatory agent that inhibits the function of activated macrophages. VIP was shown to inhibit IL-6, TNFalpha, IL-12, chemokine, and nitric oxide production in endotoxin-activated macrophages. The present study reports the effect of VIP on IL-8 production by stimulated human monocytes. VIP inhibits IL-8 production in a dose- and time-dependent manner at the mRNA level. The specific VPAC1 receptor mediates the inhibitory effect of VIP. Two transduction pathways appear to be involved, a major cAMP-independent pathway and a secondary cAMP-dependent pathway. Of obvious physiological significance is the fact that VIP, presumably through the inhibition of IL-8 production, dramatically reduces the monocyte-induced neutrophil chemotaxis, an important event in the pathogenesis of several inflammatory and autoimmune disorders. These findings support the proposed role of VIP as a key endogenous anti-inflammatory agent and describe a novel mechanism, i.e., the inhibition of the production of monocyte-derived IL-8. (C) 2003 Elsevier Science (USA). All rights reserved.

引用

页码：825 / 832

页数：8

共 52 条

[1]

BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97

[2] Human chemokines: An update [J].

Baggiolini, M ;

Dewald, B ;

Moser, B .

ANNUAL REVIEW OF IMMUNOLOGY, 1997, 15 :675-705

[3]

BOUMA MG, 1994, J IMMUNOL, V153, P4159

[4] ENDOTOXEMIA IN HUMAN SEPTIC SHOCK [J].

DANNER, RL ;

ELIN, RJ ;

HOSSEINI, JM ;

WESLEY, RA ;

REILLY, JM ;

PARILLO, JE .

CHEST, 1991, 99 (01) :169-175

[5] Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit interleukin-12 transcription by regulating nuclear factor κB and Ets activation [J].

Delgado, M ;

Ganea, D .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (45) :31930-31940

[6] VIP and PACAP38 modulate cytokine and nitric oxide production in peritoneal macrophages and macrophage cell lines [J].

Delgado, M ;

Munoz-Elias, EJ ;

Martinez, C ;

Gomariz, RP ;

Ganea, D .

NEUROPEPTIDES: STRUCTURE AND FUNCTION IN BIOLOGY AND BEHAVIOR, 1999, 897 :401-414

[7] Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit tumor necrosis factor α transcriptional activation by regulating nuclear factor-kB and cAMP response element-binding protein/c-Jun [J].

Delgado, M ;

Munoz-Elias, EJ ;

Kan, YQ ;

Gozes, I ;

Fridkin, M ;

Brenneman, DE ;

Gomariz, RP ;

Ganea, D .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (47) :31427-31436

[8]

Delgado M, 1999, J IMMUNOL, V162, P4685

[9]

Delgado M, 1999, J IMMUNOL, V163, P4213

[10]

Delgado M, 1999, J IMMUNOL, V162, P2358

← 1 2 3 4 5 6 →